Subcommittee on Factor VIII, Factor IX & Rare Coagulation Disorder: Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia
The scope of this recommendation is to provide guidance for reporting of inhibitor cases in previously treated patients (PTPs) with hemophilia A. This guidance is intended to improve transparency and completeness of reporting of observed events; it does not cover planning, executing or analyzing original studies aimed at the assessment of inhibitor rates. Read more.
Subcommittee on Women's Health Issue in Thrombosis and Hemostasis: Management of direct oral anticoagulants in women of childbearing potential Many patients receiving oral anticoagulation for VTE are in their reproductive years, but the potential for reproductive toxicity of DOACs in humans in unknown, and there are no adequate data on the use of DOACs in pregnant women via maternal or paternal exposure. Accordingly, the DOAC SPCs recommend against their use in pregnancy and during breastfeeding [1-3]. However, patients may unintentionally become pregnant while taking DOAC therapy. Read more.